A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer

Trial Profile

A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2014

At a glance

  • Drugs Iofolastat I-123 (Primary) ; Capromab
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Sponsors Molecular Insight Pharmaceuticals
  • Most Recent Events

    • 15 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top